Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2044-5385
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma ; volume:8 ; number:8 ; day:31 ; month:7 ; year:2018 ; pages:1-4 ; date:8.2018
Blood cancer journal ; 8, Heft 8 (31.7.2018), 1-4, 8.2018
- Urheber
-
Sivaraj, Dharshan
- Beteiligte Personen und Organisationen
-
Green, Michael M.
Kang, Yubin
Long, Gwynn D.
Rizzieri, David A.
Li, Zhiguo
Garrett, Anderson H.
McIntyre, Jackie L.
Chao, Nelson J.
Gasparetto, Cristina
SpringerLink (Online service)
- DOI
-
10.1038/s41408-018-0104-5
- URN
-
urn:nbn:de:101:1-2018100220442051937073
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 05:29 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sivaraj, Dharshan
- Green, Michael M.
- Kang, Yubin
- Long, Gwynn D.
- Rizzieri, David A.
- Li, Zhiguo
- Garrett, Anderson H.
- McIntyre, Jackie L.
- Chao, Nelson J.
- Gasparetto, Cristina
- SpringerLink (Online service)
Ähnliche Objekte (12)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis